MS Research Foundation

A forum to discuss Chronic Cerebrospinal Venous Insufficiency and its relationship to Multiple Sclerosis.

MS Research Foundation

Postby 1eye » Thu Mar 24, 2011 2:24 pm

http://mssociety.ca/en/research/researchprojects.htm

In wading through this I note there seem to be a lot of databases and registries. Perhaps CCSVI treatment can piggyback on some of this and save some $? There may already be duplication, but I think CCSVI information is not being collected in Canada so far. As far as MS Clinics go, it still doesn't exist. People who have gone abroad are being "followed". Though the places where they were treated probably have records, I doubt they are being asked for them.

These studies below, are just the Canadians! Hell, no matter what they find elsewhere, here in Canada we're bound to have a cure all our own, with all the money we're spending...

In its first 60 years, donors to the Society have made it possible to provide over $110 million in funding for Canada’s world-class researchers, enabling them to explore new ideas and participate in international clinical trials of new medications. The Society also provides vital seed money for new avenues of research, and promotes the development of the next generation of scientists and clinicians working to find a cure for MS. The MS Society now provides over $10 million per year to MS research.

The MS Society also funds the MS Scientific Research Foundation, which supports large collaborative scientific projects. Over the next three years, the Foundation will spend another $12 million on MS research.


Guillermina Almazan, Ph.D., and Walter Mushynski, Ph.D.
McGill University, Montréal
$300,000
(April 1, 2009 – March 31, 2012)
Role of p38 MAPK (mitogen activated-protein kinase) Signaling Pathways in
Myelination

Jack Antel, M.D.
McGill University, Montréal
$219,900
(April 1, 2010 – March 31, 2012)
Promoting Remyelination in Multiple Sclerosis

Jack Antel, M.D.
McGill University, Montréal
$236,500
(April 1, 2009 – March 31, 2011)
Cellular Immune Injury of Human Oligodendrocytes

Jack Antel, M.D.
McGill University, Montréal
$233,200
(April 1, 2009 – March 31, 2011)
Microglia as Regulators of the Immune Response in the Central Nervous System

Nathalie Arbour, Ph.D.
Research Centre of the University of Montréal Hospital Centre (CR-CHUM)
$330,000
(April 1, 2009 – March 31, 2012)
Detrimental Dialogue Between the Immune System and the Central Nervous
System: Roles of CD8 T Lymphocytes

Douglas Arnold, M.D., Ph.D.
McGill University, Montréal
$240,000
(April 1, 2009 – March 31, 2011)
Imaging Inflammation in Multiple Sclerosis

Douglas Arnold, M.D., Ph.D.
McGill University, Montréal
$264,350
(April 1, 2008 – March 31, 2011)
Imaging Demyelination and Remyelination in Multiple Sclerosis

Joan Boggs, Ph.D.
Hospital for Sick Children, Toronto
$332,435
(April 1, 2010 – March 31, 2013)
Function of the membrane estrogen receptor in oligodendrocytes/myelin

Andrew Chojnacki, Ph.D.
University of Calgary
$160,430
(April 1, 2010 – March 31, 2012)
Regulation of human oligodendrogenesis by Nodal signaling

Samuel David, Ph.D.
McGill University, Montréal
$279,431
(April 1, 2008 – March 31, 2011)
Role of Prostaglandins D2, E2, and their Receptors in EAE

Shannon Dunn, Ph.D.
University of Toronto, Toronto
$221,224
(April 1, 2009 – March 31, 2011)
PPARalpha as a Mediator of Sex Differences in Autoimmunity

Shannon Dunn, Ph.D.
University Health Network, Toronto
$211,100
(April 1, 2010 – March 31, 2012)
PPARdelta and PPARgamma as negative regulators of innate inflammation in EAE

Eleanor Fish, Ph.D.
Toronto General Research Institute
$252,650
(April 1, 2009 – March 31, 2011)
The Role of IFN-ß in the Pathogenesis of Multiple Sclerosis

Paula Foster, Ph. D.
Robarts Research Institute, London
$209,956
(April 1, 2009 – March 31, 2011)
The Use of Cellular MRI to Evaluate Stem Cell Transplantation in a Model of Multiple
Sclerosis

Alyson Fournier, Ph.D.
Montréal Neurological Institute, McGill University
$399,980
(April 1, 2010 – March 31, 2013)
Immune cell influences on neuronal viability and repair

Sylvie Fournier, Ph.D.
McGill University, Montréal
$178,180
(April 1, 2010 – March 31, 2012)
Pathogenic mechanisms in an animal model of CD8+ T cell-mediated demyelinating
disease

Jennifer Gommerman, Ph.D.
University of Toronto
$408,335
(April 1, 2010 – March 31, 2013)
Understanding the role of TNF super-family members in EAE/MS pathology

Tim Kennedy, Ph.D.
McGill University, Montréal
$311,718
(April 1, 2008 – March 31, 2011)
Netrin Function in the Development of Axonal-Oligodendroglial Interactions

Bradley Kerr, Ph.D.
University of Alberta, Edmonton
$148,912
(April 1, 2009 – March 31, 2011)
Examining Novel Targets to Treat Neuropathic Pain in Multiple Sclerosis: The
Glutamate Transporters

Rashmi Kothary, Ph.D.
Ottawa Health Research Institute
$304,320
(April 1, 2008 – March 31, 2011)
Integrin Linked Kinase and CNS Myelination

Steve Lacroix, Ph.D.
Université Laval, Québec
$253,178
(April 1, 2010 – March 31, 2012)
Dichotomous actions of the IL-1 system in MS

Wayne Moore, M.D.
University of British Columbia, Vancouver
$355,936
(April 1, 2008 – March 31, 2011)
The Pathologic Basis of Magnetic Resonance Imaging in Multiple Sclerosis

Alan Peterson, Ph.D.
McGill University, Montréal
$205,320
(April 1, 2010 – March 31, 2012)
Generation and characterization of a conditional model of interrupted
myelinogenesis

Christopher Power, M.D.
University of Alberta, Edmonton
$297,858
(April 1, 2009 – March 31, 2012)
Syncytin-1 and Endoplasmic Reticulum Stress in the Pathogenesis of Multiple
Sclerosis

Alexandre Prat, M.D., Ph.D.
Research Centre of the University of Montréal Hospital Centre (CR-CHUM)
$374,997
(April 1, 2009 – March 31, 2012)
Origin, Regulation and Function of Perivascular Dendritic Cells in MS

Alexandre Prat, M.D., Ph.D.
Research Centre of the University of Montréal Hospital Centre (CR-CHUM)
$330,000
(April 1, 2008 – March 31, 2011)
Novel Adhesion Molecules of the Blood-Brain Barrier Regulating Central Nervous
System Inflammation

Jacqueline Quandt, Ph.D.
University of British Columbia, Vancouver
$210,660
(April 1, 2010 – March 31, 2012)
Anti-inflammatory and neuroprotective effects of TEMPOL in models of multiple
sclerosis

Stéphane Richard, Ph.D.
Lady Davis Research Institute, Jewish General Hospital, Montréal
$319,080
(April 1, 2009 – March 31, 2012)
The Role of the Quaking Proteins in Oligodendrocyte Physiology and Myelination

Serge Rivest, Ph.D.
Université Laval, Québec
$203,914
(April 1, 2010 – March 31, 2012)
Therapeutic potential of a new subset of macrophages in animal models of MS.

George Robertson, Ph.D.
Dalhousie University, Halifax
$244,050
(April 1, 2009 – March 31, 2011)
Modulation of Apoptotic Signaling in Experimental Autoimmune Encephalomyelitis

Luc Vallières, Ph.D.
Université Laval, Québec
$221,460
(April 1, 2010 – March 31, 2012)
Recruitment of monocytes into the brain: regulation by pertussis toxin

Peter van den Elzen, M.D.
University of British Columbia, Vancouver
$165,000
(April 1, 2010 – March 31, 2013)
Lipid Antigen Presentation by B cells and EBV-infected B cells in MS

Alan Wilman, Ph.D.
University of Alberta, Edmonton
$193,256
(April 1, 2010 – March 31, 2012)
Application of High Field MRI to Multiple Sclerosis

V. Wee Yong, Ph.D.
University of Calgary
$394,662
(April 1, 2010 – March 31, 2013)
Promoting remyelination by overcoming an inhibitory microenvironment

CLINICAL AND POPULATION HEALTH

Lenora Brown, M.D.
University of Calgary
$42,580.45
(April 1, 2010 – March 31, 2011)
Measures of Corpus Callosum Function in MS: Development of an Outcome Measure

Anthony Feinstein, Ph.D.
Sunnybrook Health Sciences Centre, Toronto
$134,929.50
(April 1, 2010 – March 31, 2012)
Detecting cognitive dysfunction in patients with Multiple Sclerosis: assessing the
validity of a computerized battery

Ruth Ann Marrie, M.D., Ph.D.
University of Manitoba, Winnipeg
$111,288
(April 1, 2009 – March 31, 2011)
Frequency of Comorbidity in Multiple Sclerosis

Anthony Traboulsee, Ph.D.
University of British Columbia, Vancouver
$92,768
(April 1, 2009 – March 31, 2011)
Improving Safety Monitoring and Design of Future Multiple Sclerosis Clinical Trials
Using Historical MRI Data

Daria Trojan, Ph.D.
McGill University, Montréal
$201,670
(April 1, 2009 – March 31, 2011)
Sleep Abnormalities in Multiple Sclerosis: Potential Benefits of Treatment and
Effect on Neurodegeneration

FOUNDATION AWARDS

Brenda Banwell, M.D., Hospital for Sick Children, Toronto
Amit Bar‐Or, M.D., Montreal Neurological Institute, Montreal
Dessa Sadovnick, Ph.D., University of British Columbia, Vancouver
Douglas Arnold, M.D. , Montreal Neurological Institute, Montreal
Ruth Ann Marrie, M.D., Ph.D., University of Manitoba, Winnipeg
$4,300,000

Prospective Study of the Clinical Epidemiology, Pathobiology, & Neuroimaging
Features of Canadian Children with Acquired Demyelinating Syndromes

George Ebers, M.D., University of Oxford
Dessa Sadovnick, Ph.D., University of British Columbia, Vancouver
$4, 453,477

Canadian Collaborative Project on Genetic Susceptibility to MS (CCPGSMS) –
Molecular Genetics

Mark Freedman, M.D., Ottawa Hospital Research Institute, Ottawa
Harold Atkins, M.D., Ottawa Hospital Research Institute, Ottawa
$2,419,701

Long Term Outcomes Following Immunoablative Therapy and Autologous Stem Cell
Transplant for Poor Prognosis MS

Luanne Metz, M.D., University of Calgary
$4,047,255

Phase III double-blind, randomized, placebo-controlled trial of minocycline in
clinically isolated syndromes (CIS)
Dessa Sadovnick, Ph.D., University of British Columbia, Vancouver

George Ebers, M.D., University of Oxford
$4,502,164

Canadian Collaborative Project on Genetic Susceptibility to MS (CCPGSMS) –Phase 5:
Genetic Epidemiology & Databases, including DNA Bank

PILOT GRANTS

Dr. Andrew Emili
University of Toronto
$35,000
(January 1, 2010 – December 31, 2010)
A neuroproteomics assessment of multiple sclerosis

Dr. Anthony Feinstein
Sunnybrook Health Sciences Centre
$35,000
(January 1, 2010 – December 31, 2010)
Validation and feasibility of an internet-based approach to cognitive assessment

Dr. Stacey Hart
Ryerson University
$30,250
(January 1, 2010 – December 31, 2010)
Illness uncertainty, relationship dynamics, and distress in couples facing MS

Dr. Margaret Schneider
Wilfrid Laurier University
$21,605
(January 1, 2010 – December 31, 2010)
Physical Activity Participation and Access Among Individuals Living with MS in
Ontario

Dr. Maria Vrontakis
University of Manitoba
$35,000
(January 1, 2010 – December 31, 2010)
Role of Galanin on CNS remyelination in a cuprizone model of MS

DONALD PATY CAREER DEVELOPMENT AWARDS

Dr. Nathalie Arbour
Research Centre of the University of Montréal Hospital Centre (CR-CHUM)
$150,000
(July 1, 2008 – June 30, 2011)

Dr. Bradley Kerr
University of Alberta
$150,000
(July 1, 2009 – June 30, 2012)

Dr. Shalina Ousman
University of Calgary
$150,000
(July 1, 2009 – June 30, 2012)

Dr. Jacqueline Quandt
University of British Columbia
$150,000
(July 1, 2010 – June 30, 2013)

Dr. Helen Tremlett
University of British Columbia
$150,000
(July 1, 2010 – June 30, 2013)

POSTDOCTORAL FELLOWSHIPS

RECIPIENT SUPERVISOR INSTITUTION PROJECT TITLE
Dr. Sura Alwan

Dr. Dessa
Sadovnick
University of
British
Columbia
A North American Multiple
Sclerosis Pregnancy
Registry
Dr. Joseph Antony Dr. Shannon
Dunn
The Hospital
for Sick
Children
To study the role of PPARs
as negative regulators of
innate neuroinflammation
Dr. Vladimir Bamm Dr. George
Harauz
University of
Guelph
Interrelationships between
phosphorylation and
citrullination in 18.5 kDa
MBP and their effect on
calmodulin binding and on
interactions with actin,
tubulin and divalent metal
cations
Dr. Benoit Barrette Dr. Klaus-Armin
Nave
Max-Planck
Institute
Characterization of the
inflammatory response in
the CNS of Cnp1Cre*Pex5
mice presenting a
peroxisome
oligodendroglial defect
Dr. Jayasree
Basivireddy

Dr. Jacqueline
Quandt
University of
British
Columbia
A novel role of SPARC in
multiple sclerosis
regenerative therapies
Dr. Zhihong Chen

Dr. Bruce Trapp Cleveland Clinic Neuroprotective effect of
LPS-preconditioned
microglia

Dr. Ajit Singh
Dhaunchak
Dr. David
Coleman
McGill
University
Role of tmem10 and tmeff2
in myelination and CNS
development
Dr. Axinia
Samentha Doering
Dr. Wee Yong University of
Calgary
Promoting remyelination in
demyelinating models
Dr. Lama Fawaz

Dr. Amit Bar-Or McGill
Univesity
B cell effector responses in
Pediatric ADS and other
autoimmune diseases
Dr. Debra Fulton Dr. Alan
Peterson
The University
of British
Columbia
Identification and
validation of the
transcription factor
binding sites and 35
transcription factor
cooperativity relationships
that control expression of
myelin-associated genes in
oligdendrocytes
Dr. Georgina Galicia
Rosas
Dr. Jennifer
Gommerman
University of
Toronto
Evaluating the mechanism
of action of LTBR-Ig in EAE
Dr. Steve Gendron Dr. Alexandre
Prat
Centre de
recherche du
Chum
Role of integrin
alpha8beta1 and
semaphorin/plexin in
multiple sclerosis
Dr. Denis Gris

Dr. Jenny Ting University of
North Carolina
at Chapel Hill
Role of Nlrs in multiple
sclerosis
Dr. Dong Han

Dr. Timothy
Kennedy
McGill
University
Mechanisms Regulating
the Formation and
Maintenance of CNS
Myelin
Dr. Andrew Jarjour Dr. Charles
Ffrench-
Constant
University of
Edinburgh
Investigating the role of
polarity complex in
oligodendrocyte
development, myelination,
and remyeliantion
Dr. Sukhdev Singh
Kamboj

Dr. Sam David McGill
University
Role of prostaglandin D2,
E2 and their Receptors in
Experimental Autoimmune
Encephalomyelitis
Dr. Elaine Kingwell Dr. Helen
Tremlett
University of
British
Columbia
Survival and predictors of
mortality in the British
Columbian Multiple
Sclerosis Population
Dr. Shannon Kolind Drs. Heidi
Johansen-Berg
and Sean Deoni
University of
Oxford
Correlating Magnetic
Resonance Changes with
Clinical Multiple Sclerosis
Symptoms: Whole Brain
Multi-Component
Relaxation along Specific
Fibre Pathways
Dr. Sébastien
Lévesque
Dr. Steve
Lacroix
Université
Laval
Dichotomous actions of
the IL-1 system in MS
Dr. Samantha
Lloyd-Burton
Dr. Jane
Roskams
University of
British
Columbia
The role of the
matricellular protein
SPARC in the regulation of
microglial processes during 36
MS pathogenesis
Dr. Veronique
Miron
Dr. Charles
Ffrench-
Constant
University of
Edinburgh
Identification of
inflammatory cytokines
that promote
oligodendrocyte-mediated
myelination and
remyelination: implications
for multiple sclerosis
Dr. Danette Nicolay Dr. Wendy
Macklin
University of
Colorado
Denver
Retinoic acid signalling in
oligodendrocyte
development
Dr. Jiwon Oh

Dr. Peter
Calabresi
University of
Toronto
7-Tesla MRI Correlates of
Cognitive Dysfunction in
Multiple Sclerosis (MS)
Dr. Scott Ryan Dr. Rashmi
Kothary
Ottawa Health
Research
Institute
Organelle specific
dysfunction in a mouse
model of MS
Dr. Raphael
Schneider
Dr. Nathalie
Arbour
Centre de
Recherche du
CHUM
Modulation of CD8 T cell
functions by IL-27 and IL-15
in the context of multiple
sclerosis
Dr. Emilie Viel Dr. Nathalie
Arbour
Centre
hospitalier de
l'université de
Montréal
MCAM implication in
blood-brain barrier
endothelial cells activation
and interaction with
immune cells in the
context of MS
Dr. Jing Wang

Dr. Freda Miller The Hospital
for Sick
Children
The atypical PKC-CBP
pathway and
oligodendrocyte genesis
Dr. Yunling Wang

Dr. Stéphane
Richard
McGill
University
Characterizing the link
between miRNAs and the
QKI proteins in
oligodendrocytes.

RESEARCH STUDENTSHIPS

Ph.D. Studentship
RECIPIENT SUPERVISOR INSTITUTION PROJECT TITLE
Erik Bélanger Dr. Daniel Côté Université
Laval
In vivo evaluation of MS-
like lesions with nonlinear
microscopy
Elodie Brison Dr. Pierre
Talbot
INRS-Institut
Armand-
Frappier
From respiratory disease
to multiple sclerosis-like
disability: importance of
the spike protein of human
respiratory coronavirus
OC43
Sarah-Jane Bull Dr. Timothy
Kennedy
Montreal
Neurological
Institute
The role of DCC in
paranodal junctions and
myelin maintenance
Zografos
Caramanos
Dr. Douglas
Arnold
McGill
University
The Use and Utility of
Quantitative Magnetic
Resonance Imaging at
Describing
Neuropathology and
Predicting Future Disability
in Patients with Multiple
Sclerosis
Danielle Culp Dr. Stacey Hart Ryerson
University
Sexual Dysfunction and
Sexual Satisfaction among
those with Multiple
Sclerosis: How Can the
Illness Intrusiveness Model
Help Explain the
Relationship?
Miguel De Avila Dr. George
Harauz
University of
Guelph
Myelin basic protein
interactions with SH3
domains
Marcio Luiz De
Paula
Dr. Guillermina
Almazan
McGill
University
Role of IGF-1 signalling in
oligodendrocyte
development, myelination
and remyelination
Trisha Finlay Dr. Shalina
Ousman
University of
Calgary
The role of alphaB-
crystallin in
oligodendrocyte function.
Rezwan Ghassemi Dr. Doug Arnold McGill MRI measures of brain 38
University injury in Children with MS
Alan Gillett Dr. Tomas
Olsson
Karolinska
Institutet
Genetic and Functional
Mechanisms Regulating
Neuroinflammation

Yoko Ishigami Dr. Raymond
Klein
Dalhousie
University
Measuring the
components of attention
in ms patients using the
Attention Network Test
(ANT)
Saeed Kalantari Dr. Alex
MacKay
University of
British
Columbia
Myelin Water
Measurements in Multiple
Sclerosis: The Role of
Water Exchange
Allison Kraus Dr. Marek
Michalak
University of
Alberta
Dysmyelination in the
Calnexin-Deficient Mouse
Ayse Kuspinar Dr. Nancy Mayo McGill
University
Physical, mental and
immunomodulatory
effects of exercise in
persons with multiple
sclerosis
Dina Lafoyiannis Drs. Brenda
Banwell and
Mary Desrocher
The Hospital
for Sick
Children
Optical Coherence
Tomography, MRI
outcomes and Cognition in
Pediatric Multiple Sclerosis
Catherine
Larochelle, M.D.
Dr. Alexandre
Prat
Centre
hospitalier de
l'université de
Montréal
MCAM implication in
blood-brain barrier
endothelial cells activation
and interaction with
immune cells in the
context of MS
Ashleigh McLean Dr. Steffany
Bennett
University of
Ottawa
Examining the role of Cx32
in demyelination following
EAE disease induction
John-Paul Michalski Dr. Rashmi
Kothary
Ottawa Health
Research
Institute
A role for integrin-linked
kinase in oligodendrocyte
mediated myelination of
the central nervous system
Ryan O'Meara Dr. Rashmi
Kothary
Ottawa Health
Research
Institute
The role of integrin-linked
kinase in oligodendrocyte
development
Natalia Pikor Dr. Jennifer
Gommerman
University of
Toronto
Dissecting immune
function and gene
alterations in chronic 39
versus relapsing EAE
Camille Pittet Dr. Nathalie
Arbour
Centre
hospitalier de
l'université de
Montréal
Potential
immunoregulartory roles
of programmed-cell death -
1 ligands in human central
nervous system
Katrin Schulz Dr. Samuel
David
McGill
University
Iron efflux mechanism in
CNS glia cells
Graham Smith Dr. George
Harauz
University of
Guelph
Investigating cytoskeltal
interactions of myelin basic
protein in developing
oligodendrocyte cells
Wulin Teo Dr. Peter Stys University of
Calgary
Cellular and molecular
mechanisms of axon
spheroid formation in an
ex-vivo model of axonal
injury
Pei-Shan Wang Dr. Catherine
Pallen
University of
British
Columbia
The role of protein tyrosine
phosphatase  (PTP) in
CNS myelination
Magdalena
Wojtowicz
Dr. John Fisk Dalhousie
University
Functional and Structural
Neural Correlates of
Cognitive Functioning in
Multiple Sclerosis
Xiaojun Xie Dr. Vanessa
Auld
The University
of British
Columbia
Characterizaiton of
integrins in Drosophila glial
cells


M.Sc. Studentship
RECIPIENT SUPERVISOR INSTITUTION PROJECT TITLE
Nadine Akbar Dr. Anthony
Feinstein
Sunnybrook
Health
Sciences
Centre
Validation of an internet
version of the multiple
sclerosis
neuropsychological
questionnaire
Mark Akins Dr. Steffany
Bennett
University of
Ottawa
Targeting connexin32
(Cx32) to promote
remyelination of damaged
optic tract and corpus
callosum
Haim Ben Ami Dr. Roger Tam The University
of British
Columbia
Accurate and Reproducible
Methods for MRI
Morphometry of the 40
Corpus Callosum in
Multiple Sclerosis Patients
Jochen Fahr Dr. Michael
Kallos
University of
Calgary
Protein Production and
Purification using Murine
Embryonic Stem Cells –
Process Engineering and
Evaluation using a Target
Protein for the Treatment
of Multiple Sclerosis
Kimia Honarmand Dr. Anthony
Feinstein
Sunnybrook
Health
Sciences
Centre
Cannabis use in multiple
sclerosis: A cognitive and
neuroimaging study
Michael Keough Dr. Wee Yong University of
Calgary
Altering the
Microenvironment to
Promote Remyelination
Antonia Kobert Dr. Amit Bar-Or McGill
University
Effects of Inflammatory
Glial-Cell Derived Factors
on B-Cell Activation of T
Cells in MS
Shruti
Krishnamoorthy
Dr. Paula Foster The University
of Western
Ontario
The use of Cellular MRI to
Evaluate Stem Cell
Transplantation in a Model
of Multiple Sclerosis
Marc-André
Lécuyer
Dr. Alexandre
Prat
Université de
Montréal
The Role of ALCAM in the
Murine Model of Multiple
Sclerosis EAE
(Experimental
Autoimmune
Encephalomyelitis)
Joshua Lee Dr. Dessa
Sadovnick
University of
British
Columbia
Canadian Asians with
multiple sclerosis (CAMS)
study
Ellen Meng-I Lu Dr. Helen
Tremlett
The University
of British
Columbia
Adverse Pregnancy-
Related and Birth
Outcomes in Multiple
Sclerosis
Alma Mohebiany Dr. Nathalie
Arbour
Centre
hospitalier de
l'université de
Montréal
Establishing the in vivo
contribution of interleukin-
15 to the pathogenesis of
multiple sclerosis and its
animal models
Amy Styles Dr. Christina
Wolfson
McGill
University
Environmental and lifestyle
risk factors for multiple
"Try - Just A Little Bit Harder" - Janis Joplin
CCSVI procedure Albany Aug 2010
'MS' is over - if you want it
Patients sans/without patience
User avatar
1eye
Family Elder
 
Posts: 2997
Joined: Wed Mar 17, 2010 3:00 pm
Location: Kanata, Ontario, Canada

Advertisement

Postby ikulo » Thu Mar 24, 2011 2:29 pm

Cool find! Thanks 1eye.
User avatar
ikulo
Family Elder
 
Posts: 444
Joined: Tue Aug 04, 2009 2:00 pm
Location: colorado

total

Postby 1eye » Thu Mar 24, 2011 6:50 pm

If you've scrolled this far you deserve a total. You can check my addition, but I make it $30,224,679.95

None, of course, on CCSVI research. There *is* one on perivascular dendrocytes, though.

For those intrigued, the 95 cents is a total of two studies, one that includes 50 cents, and one 45 cents.
"Try - Just A Little Bit Harder" - Janis Joplin
CCSVI procedure Albany Aug 2010
'MS' is over - if you want it
Patients sans/without patience
User avatar
1eye
Family Elder
 
Posts: 2997
Joined: Wed Mar 17, 2010 3:00 pm
Location: Kanata, Ontario, Canada

Postby Cece » Thu Mar 24, 2011 7:12 pm

It's a disgrace. $30 million. MS is well-funded for disease research, yet the break-through came in Italy from a doctor using his evening and weekend time on the hospital equipment.

Kudos to Dr. Zamboni. Kudos to the MS Society whenever they get around to seeing the light. I have no doubt that it will eventually get bright enough, even with their blinders on.
Cece
Family Elder
 
Posts: 9053
Joined: Mon Jan 04, 2010 3:00 pm

Postby ikulo » Thu Mar 24, 2011 9:03 pm

While MS is certainly more funded than other conditions, it is still in the low-to-mid level of the scale.

Keep in mind $30Million is just for Canada for that year. The NIH spends over $100 Million in additional funding for MS.

More perspective: over $700M was spent on breast cancer and about $3 Billion, yes, Billion on HIV/AIDS research each year. Cerebral Palsy only gets about $19M per year from the NIH.

Also keep in mind that this research isn't "mutually exclusive." Meaning, discoveries that are made in MS research could very well help other conditions - diabetes, lupus, stroke, etc.

http://report.nih.gov/rcdc/categories/
User avatar
ikulo
Family Elder
 
Posts: 444
Joined: Tue Aug 04, 2009 2:00 pm
Location: colorado


Return to Chronic Cerebrospinal Venous Insufficiency (CCSVI)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service

cron